为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验，建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?)，感谢您选择我们！
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| S412003-100μg |
100μg |
现货  |
| |
| S412003-1mg |
1mg |
现货 |
| |
| S412003-5mg |
5mg |
现货 |
| |
| S412003-10mg |
10mg |
期货 |
|
| 产品名称 | Sarilumab (anti-IL-6Rα), Antibody of Interleukin-6 receptor; α subunit |
|---|---|
| 英文别名 | gp80 | IL-6 receptor subunit alpha | IL-6R 1 | IL-6R subunit alpha | IL-6RA | IL-6R-alpha | Membrane glycoprotein 80 |
| 规格或纯度 | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| 特异性 | IL6R |
| 应用 | Flow,ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR) |
| 种属反应性 | Cynomolgus monkey,Human |
| 偶联 | Unconjugated |
| 作用类型 | 拮抗剂 |
| 作用机制 | Antibody of Interleukin-6 receptor; α subunit |
| 抗体类型 | Primary antibody |
|---|---|
| 克隆类型 | Recombinant |
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 27.0 kDa (Light Chain) & 51.9 kDa (Heavy Chain), under reducing conditions; 186.5 kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 纯度 | >95% |
| 来源 | CHO supernatant |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | Lot by Lot |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS编号和信息 | 1189541-98-7 |
Sarilumab (anti-IL-6Rα) (S412003) - Flow Cytometry
Flow Cytometry analysis of U937 cells labelling IL-6Rα (red) with Sarilumab (anti-IL-6Rα) (S412003). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Sarilumab (anti-IL-6Rα) (S412003) - SEC
The purity of Sarilumab (anti-IL-6Rα) (S412003) is more than 95% verified by HPLC.
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
 ZJ24F0102631 |
分析证书 | 24-01-26 | S412003 |
| 1. Strand V, Reaney M, Chen CI, Proudfoot CW, Guillonneau S, Bauer D, Mangan E, Graham NM, van Hoogstraten H, Lin Y et al.. (2017) Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.. RMD Open, 3 (1): (e000416). [PMID:28326189] [10.1021/op500134e] |
| 2. Boyapati A, Msihid J, Fiore S, van Adelsberg J, Graham NM, Hamilton JD. (2016) Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.. Arthritis Res Ther, 18 (1): (225). [PMID:27716324] [10.1021/op500134e] |
| 3. Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, van Hoogstraten H, Bauer D, Ignacio Vargas J, Lee EB. (2017) Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.. Ann Rheum Dis, 76 (5): (840-847). [PMID:27856432] [10.1021/op500134e] |
| 4. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P et al.. (2004) The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).. Genome Res, 14 (10B): (2121-7). [PMID:15489334] [10.1021/op500134e] |
| 5. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K et al.. (2004) Complete sequencing and characterization of 21,243 full-length human cDNAs.. Nat Genet, 36 (1): (40-5). [PMID:14702039] [10.1021/op500134e] |
| 6. Varghese JN, Moritz RL, Lou MZ, Van Donkelaar A, Ji H, Ivancic N, Branson KM, Hall NE, Simpson RJ. (2002) Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain.. Proc Natl Acad Sci USA, 99 (25): (15959-64). [PMID:12461182] [10.1021/op500134e] |
| 7. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. (2003) Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex.. Science, 300 (5628): (2101-4). [PMID:12829785] [10.1021/op500134e] |
| 8. Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M, Breedveld E, 't Hart B, Poelmans S, Bontinck L et al.. (2015) The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.. Arthritis Res Ther, 17 (13): (135). [PMID:25994180] [10.1021/op500134e] |
| 1. Strand V, Reaney M, Chen CI, Proudfoot CW, Guillonneau S, Bauer D, Mangan E, Graham NM, van Hoogstraten H, Lin Y et al.. (2017) Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.. RMD Open, 3 (1): (e000416). [PMID:28326189] [10.1021/op500134e] |
| 2. Boyapati A, Msihid J, Fiore S, van Adelsberg J, Graham NM, Hamilton JD. (2016) Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.. Arthritis Res Ther, 18 (1): (225). [PMID:27716324] [10.1021/op500134e] |
| 3. Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, van Hoogstraten H, Bauer D, Ignacio Vargas J, Lee EB. (2017) Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.. Ann Rheum Dis, 76 (5): (840-847). [PMID:27856432] [10.1021/op500134e] |
| 4. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P et al.. (2004) The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).. Genome Res, 14 (10B): (2121-7). [PMID:15489334] [10.1021/op500134e] |
| 5. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K et al.. (2004) Complete sequencing and characterization of 21,243 full-length human cDNAs.. Nat Genet, 36 (1): (40-5). [PMID:14702039] [10.1021/op500134e] |
| 6. Varghese JN, Moritz RL, Lou MZ, Van Donkelaar A, Ji H, Ivancic N, Branson KM, Hall NE, Simpson RJ. (2002) Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain.. Proc Natl Acad Sci USA, 99 (25): (15959-64). [PMID:12461182] [10.1021/op500134e] |
| 7. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. (2003) Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex.. Science, 300 (5628): (2101-4). [PMID:12829785] [10.1021/op500134e] |
| 8. Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M, Breedveld E, 't Hart B, Poelmans S, Bontinck L et al.. (2015) The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.. Arthritis Res Ther, 17 (13): (135). [PMID:25994180] [10.1021/op500134e] |
首页
400-620-6333
